P. Golovics

发表

Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort

P. Lakatos, K. Gecse, L. Lakatos, 2015, Scandinavian journal of gastroenterology.

Have Biologics Changed the Natural History of Crohn's Disease?

P. Lakatos, M. Mandel, P. Miheller, 2014, Digestive Diseases.

Prospective, Multicentre, Nationwide Clinical Data from 600 Cases of Acute Pancreatitis

J. Gervain, P. Hegyi, Z. Rakonczay, 2016, PloS one.

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?

T. Bessissow, P. Golovics, P. Lakatos, 2022, Biomedicines.

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database

P. Lakatos, Z. Végh, P. Golovics, 2018, BMC Gastroenterology.

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn's Disease.

M. Papp, P. Lakatos, Z. Shums, 2015, Journal of Crohn's & colitis.

Inflammatory bowel disease course in Crohn's disease: is the natural history changing?

P. Lakatos, M. Mandel, P. Golovics, 2014, World journal of gastroenterology.

Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.

K. Farkas, T. Molnár, M. Papp, 2013, Journal of gastrointestinal and liver diseases : JGLD.

Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.

K. Farkas, T. Molnár, P. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

W. Afif, T. Bessissow, P. Golovics, 2021, World journal of gastroenterology.

Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study

A. Bitton, P. Lakatos, G. Wild, 2021, Digestive Diseases and Sciences.

Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.

A. Cohen, A. Bitton, Y. Xiao, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes.

P. Lakatos, G. Rudas, Z. Végh, 2018, Journal of gastrointestinal and liver diseases : JGLD.

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

K. Farkas, T. Molnár, P. Lakatos, 2014, The European Journal of Health Economics.

Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

K. Farkas, T. Molnár, P. Lakatos, 2014, The European Journal of Health Economics.

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

A. Bitton, G. Wild, W. Afif, 2022, Journal of clinical medicine.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

A. Bitton, G. Wild, W. Afif, 2022, World journal of gastroenterology.

New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe.

P. Lakatos, Z. Végh, P. Golovics, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease

G. Rogler, S. Vavricka, P. Lakatos, 2016, Scandinavian journal of gastroenterology.

Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012).

P. Lakatos, M. Mandel, L. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.

P. Lakatos, M. Mandel, L. Lakatos, 2015, World journal of gastroenterology.

Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.

K. Farkas, T. Molnár, P. Lakatos, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.

P. Lakatos, M. Szathmári, M. Mandel, 2013, Journal of Crohn's & colitis.

Is Current Smoking Still an Important Environmental Factor in Inflammatory Bowel Diseases? Results from a Population-based Incident Cohort

P. Lakatos, M. Szathmári, M. Mandel, 2013, Inflammatory bowel diseases.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

G. Veres, K. Farkas, F. Nagy, 2011, Alimentary pharmacology & therapeutics.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

G. Veres, K. Farkas, F. Nagy, 2011, Orvosi Hetilap.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Su1331 Is Hospitalization Predicting the Disease Course in Crohn's Disease? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Crohn's Disease in a Population Based Inception Cohort Between 2000-2012

P. Lakatos, M. Mandel, L. Lakatos, 2014 .

The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center.

A. Bitton, P. Lakatos, G. Wild, 2020, Journal of gastrointestinal and liver diseases : JGLD.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Is profession associated with fear of death

B. K. Thege, J. Pilling, K. Hegedűs, 2014 .

Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.

M. Péntek, P. Baji, V. Brodszky, 2016, Value in health regional issues.

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.

K. Farkas, T. Molnár, T. Resál, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.

G. Veres, M. Papp, P. Lakatos, 2014, Journal of Crohn's & colitis.

Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011.

G. Veres, P. Lakatos, M. Mandel, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977–2009

G. Veres, P. Lakatos, M. Szathmári, 2012, The American Journal of Gastroenterology.

Is early limited surgery associated with a more benign disease course in Crohn's disease?

G. Veres, P. Lakatos, M. Mandel, 2013, World journal of gastroenterology.

Risk of colorectal cancer in Crohn's disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary.

P. Lakatos, M. Mandel, L. Lakatos, 2013, Journal of gastrointestinal and liver diseases : JGLD.

P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2017, Journal of Crohn's & colitis.

Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.

P. Lakatos, M. Mandel, L. Lakatos, 2013, World journal of gastroenterology.

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

K. Farkas, T. Molnár, P. Lakatos, 2017, BMC Gastroenterology.

[The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron's disease, in Veszprém county, Hungary, a population-based cohort study].

P. Lakatos, M. Szathmári, L. Lakatos, 2012, Orvosi hetilap.

Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.

P. Lakatos, M. Szathmári, M. Mandel, 2015, World Journal of Gastroenterology.

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

T. Bessissow, P. Golovics, L. Gonczi, 2021, Journal of clinical medicine.

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis

W. Afif, T. Bessissow, P. Golovics, 2021, ACG Case Reports Journal.

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.

K. Farkas, T. Molnár, P. Lakatos, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

‘Treat to Target' - Lessons Learnt

P. Lakatos, Z. Végh, P. Golovics, 2016, Digestive Diseases.

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease

A. Bitton, G. Wild, W. Afif, 2021, Canadian journal of gastroenterology & hepatology.

Mo1843 - Non-Medical Mandatory Reversed and Back and Forth Switch Between Infliximab and its Biosimilar: Early Clinical Outcomes

K. Farkas, T. Molnár, P. Lakatos, 2018 .

P694 Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes

T. Molnár, P. Lakatos, Z. Szepes, 2018 .

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Sa1936 Efficacy and Safety of Biosimilar Infliximab After One-Year: Results From a Prospective Nationwide Cohort

K. Farkas, T. Molnár, P. Lakatos, 2016 .

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020

L. Lakatos, G. Dávid, T. Pandur, 2023, Journal of clinical medicine.

Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists

P. Lakatos, M. Péntek, P. Baji, 2016, Scandinavian journal of gastroenterology.

F. Nagy, M. Papp, P. Lakatos, 2015 .

K. Farkas, T. Molnár, M. Papp, 2015 .

Sa1156 Accelerated Treatment Strategy in Inflammatory Bowel Diseases; Is It Associated With a Change in the Disease Course?

K. Farkas, T. Molnár, M. Papp, 2015 .

Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.

K. Farkas, T. Molnár, P. Sarlós, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015

A. Bitton, G. Wild, W. Afif, 2022, Journal of clinical medicine.

[Professions and fear of death--are they correlated?].

Barna Konkolÿ Thege, J. Pilling, K. Hegedűs, 2014, Orvosi hetilap.

Incidence rates and disease course of pediatric inflammatory bowel diseases in western Hungary between 1977 – 2011

G. Veres, P. Lakatos, M. Mandel, 2014 .

Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study.

A. Bitton, A. Khoury, G. Wild, 2022, Journal of gastrointestinal and liver diseases : JGLD.

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study

A. Bitton, G. Wild, W. Afif, 2023, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.

G. Veres, M. Papp, P. Lakatos, 2014, Journal of Crohn's & colitis.